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METHODS
Study subjects
Potentially eligible patients were identified by scrutiny of hospital records, from general practice asthma clinic registers, by advertisements in local papers and from computerised general practice records.
Stable asthma: Objective confirmation by methacholine airway hyper responsiveness (airway hyperactivity determined by a ≥ 20% drop in FEV 1 at a methacholine dose of ≤ 8 mg/mL) or where this was not safe (FEV 1 < 60%) by evidence of airflow variability and a > 12% and 200 mL increase in FEV 1 following nebulised salbulamol 2.5 mg.
Sample collection
The majority of individuals (Cohort 1) had spot urine, blood and sputum samples collected during two visits in order to establish the stability of uDES and bDES levels in each group.
The period between the two visits was between 6-8 weeks and samples were collected when the subjects was stable. The remaining participants (Cohort 2) were hospitalised because of the exacerbation of COPD. Spirometry was performed in the majority of participants in both cohorts whilst only subjects in Cohort 1 had gas transfer factor for carbon monoxide (TLCO%) measured. Urine was collected in a polystyrene urine collection bottle (ThermoFisher), aliquoted and frozen at -80ºC until analysis. Plasma samples were collected in K 2 -EDTA tubes (BD Biosciences). Serum samples were collected in plain tubes (BD Biosciences). Sputum samples were collected and processed using the previous published methods (1).
uDES, bDES and sputum MMP-9 activity assays
A summary of assay performance for uDES, bDES and sputum MMP-9 activity assays is shown in On-line Supplementary Table E1 . For uDES and bDES assays, the selection of deuterium-5 isotope as an internal standard in the uDES and bDES assays was based on minimal interference signals of D 5 -DES transitions from the matrix.
RESULTS
Clinical characteristics of study cohorts
FEV1 (% predicted) in patients with stable COPD were lowest (62 ± 20%) compared to other groups in Group 1 (Table 1) . Asthmatic non-smokers and smokers also had a significant lower FEV 1 than healthy non-smokers and smokers (p<0.05, Table 1 ). There was no difference in FEV 1 between healthy non-smokers and smokers, or between asthmatic smokers and asthmatic non-smokers in Group 1. In Group 2, "during an exacerbation" COPD patients had significantly lower FEV 1 than healthy volunteers (p<0.001). In terms of TLCO%COHb, stable COPD patients had the lowest values followed by asthmatic smokers and asthmatic non-smokers (Table 1) . uDES and bDES levels in patients with stable asthma, stable and "during an exacerbation" COPD and healthy volunteers.
Similar uDES and bDES results were found in the samples collected from a subsequent visit (On-line Supplementary Table E2 ). We did not observe a significant difference between healthy non-smokers, smokers and ex-smokers (On-line Supplementary Table E2 ). There was a significant negative correlation between uDES levels and FEV 1 in healthy non-smokers but not in healthy smokers (On-line Supplementary Figure E2) . The uDES levels were not associated with disease severity (i.e. FEV 1 % predicted) in these two COPD groups although an increased variability in very severe COPD patients (FEV 1 < 30% predicted) was noticeable (On-line Supplementary Figure E2A) . We did not observe a correlation between FEV 1 and bDES levels in each group ((On-line Supplementary Figure E2B) .
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